Novel immunotherapy vaccine development

Current Opinion in Allergy and Clinical Immunology

Volumn 14, Issue 6, 2014, Pages 557-563

  Jutel, Marek ^a,b   Akdis, Cezmi A ^c  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b ALL MED Medical Research Institute   (Poland)

^c SWISS INSTITUTE OF ALLERGY AND ASTHMA RESEARCH SIAF   (Switzerland)

Author keywords

Allergen immunotherapy; Allergen immunotherapy administration routes; Novel vaccines

Indexed keywords

CARRIER PROTEIN; IMMUNOGLOBULIN E; IMMUNOLOGICAL ADJUVANT; OMALIZUMAB; PEPTIDE; RECOMBINANT ALLERGEN; VACCINE; ALLERGEN;

ALLERGEN IMMUNOTHERAPY; ALLERGIC DISEASE; ANTIGEN BINDING; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG STRUCTURE; GENETIC ENGINEERING; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOTHERAPY; INNATE IMMUNITY; MULTICENTER STUDY (TOPIC); NONHUMAN; PRIORITY JOURNAL; PROTEIN ENGINEERING; REVIEW; SUBCUTANEOUS IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; T LYMPHOCYTE; CLINICAL TRIAL (TOPIC); DRUG DESIGN; GENETICS; HYPERSENSITIVITY; IMMUNOLOGY; PROCEDURES;

ALLERGENS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; HUMANS; HYPERSENSITIVITY; IMMUNOTHERAPY; VACCINES;

EID: 84927615868     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0000000000000121     Document Type: Review

References (60)

1. Pichler U, Hauser M, Hofer H, et al. Allergen hybrids: next generation vaccines for Fagales pollen immunotherapy. Clin Exp Allergy 2014; 44:438-449.
2. Asturias JA, Ibarrola I, Arilla MC, et al. Engineering of major house dust mite allergens Der p 1 and Der p 2 for allergen-specific immunotherapy. Clin Exp Allergy 2009; 39:1088-1098.
3. Kussebi F, Karamloo F, Rhyner C, et al. A major allergen gene-fusion protein for potential usage in allergen-specific immunotherapy. J Allergy Clin Immunol 2005; 115:323-329.
4. Karamloo F, Schmid-Grendelmeier P, Kussebi F, et al. Prevention of allergy by a recombinant multiallergen vaccine with reduced IgE binding and preserved T cell epitopes. Eur J Immunol 2005; 35:3268-3276.
5. Niederberger V, Horak F, Vrtala S, et al. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci U S A 2004; 101 (Suppl 2):14677-14682.
6. Jutel M, Solarewicz-Madejek K, Smolinska S. Recombinant allergens: the present and the future. Hum Vaccin Immunother 2012; 8:1534-1543.
7. Norman P, Ohmann JL Jr, Long AA, et al. Treatment of cat allergy with T cell reactive peptides. Am J Respir Crit Care Med 1996; 154:1623-1628.
8. Müller UR, Akdis CA, Fricker M, et al. Successful immunotherapy with T cell epitope peptides of bee venom phospholipase A2 induces specific T cell anergy in bee sting allergic patients. J Allergy Clin Immunol 1998; 101:747-754.
9. Worm M, Lee HH, Kleine-Tebbe J, et al. Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy. J Allergy Clin Immunol 2011; 127:89-97; 97 e81-14.
10. Oldfield WL, Larche M, Kay AB. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet 2002; 360:47-53.
11. Pree I, Reisinger J, Focke M, et al. Analysis of epitope-specific immune responses induced by vaccination with structurally folded and unfolded recombinant Bet v 1 allergen derivatives in man. J Immunol 2007; 179: 5309-5316.
12. Akbari O, Stock P, Meyer E, et al. Essential role of NKT cells producing IL-4 and IL-13 in the development of allergen-induced airway hyperreactivity. Nat Med 2003; 9:582-588.
13. Jutel M, Jaeger L, Suck R, et al. Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol 2005; 116: 608-613.
14. Trial D. Dynavax Reports Interim TOLAMBA TM Ragweed Allergy Results from DARTT Trial [press release]. http://investors.dynavax.com/. [Accessed 15 November 2013]
15. Creticos PS, Schroeder JT, Hamilton RG, et al. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 2006; 355:1445-1455.
16. Kundig TM, Senti G, Schnetzler G, et al. Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults. J Allergy Clin Immunol 2006; 117:1470-1476.
17. Thunberg S, Neimert-Andersson T, Cheng Q, et al. Prolonged antigenexposure with carbohydrate particle based vaccination prevents allergic immune responses in sensitized mice. Allergy 2009; 64:919-926.
18. Rosewich M, Schulze J, Eickmeier O, et al. Tolerance induction after specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A in children. Clin Exp Immunol 2010; 160:403-410.
19. Niespodziana K, Focke-Tejkl M, Linhart B, et al. A hypoallergenic cat vaccine based on Fel d 1-derived peptides fused to hepatitis B PreS. J Allergy Clin Immunol 2011; 127:1562-1570.
20. Marth K, Breyer I, Focke-Tejkl M, et al. A nonallergenic birch pollen allergy vaccine consisting of hepatitis PreS-fused Bet v 1 peptides focuses blocking IgG toward IgE epitopes and shifts immune responses to a tolerogenic and Th1 phenotype. J Immunol 2013; 190:3068-3078.
21. Linhart B, Narayanan M, Focke-Tejkl M, et al. Prophylactic and therapeutic vaccination with carrier-bound Bet v 1 peptides lacking allergen-specific T cell epitopes reduces Bet v 1-specific T cell responses via blocking antibodies in a murine model for birch pollen allergy. Clin Exp Allergy 2014; 44:278-287.
22. Senti G, Prinz Vavricka BM, Erdmann I, et al. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc Natl Acad Sci U S A 2008; 105:17908-17912.
23. Hylander T, Latif L, Petersson-Westin U, Cardell LO. Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis. J Allergy Clin Immunol 2013; 131:412-420.
24. Senti G, von Moos S, Tay F, et al. Epicutaneous allergen-specific immunotherapy ameliorates grass pollen-induced rhinoconjunctivitis: a doubleblind, placebo-controlled dose escalation study. J Allergy Clin Immunol 2012; 129:129-135.
25. Zhu D, Kepley CL, Zhang M, et al. A novel human immunoglobulin Fc gamma Fc epsilon bifunctional fusion protein inhibits Fc epsilon RI-mediated degranulation. Nat Med 2002; 8:518-521.
26. Zhu D, Kepley CL, Zhang K, et al. A chimeric human-cat fusion protein blocks cat-induced allergy. Nat Med 2005; 11:446-449.
27. Senti G, Crameri R, Kuster D, et al. Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. J Allergy Clin Immunol 2012; 129:1290-1296.
28. Zaleska A, Eiwegger T, Soyer O, et al. Immune regulation by intralymphatic immunotherapy with modular allergen translocation MAT vaccine. Allergy 2014; 69:1162-1170.
29. Massanari M, Nelson H, Casale T, et al. Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. J Allergy Clin Immunol 2010; 125:383-389.
30. Begin P, Dominguez T, Wilson SP, et al. Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab. Allergy Asthma Clin Immunol 2014; 10:7.
31. Jutel M, Van de Veen W, Agache I, et al. Mechanisms of allergen-specific immunotherapy and novel ways for vaccine development. Allergol Int 2013; 62:425-433.
32. Akdis CA, Blaser K. Bypassing IgE and targeting T cells for specific immunotherapy of allergy. Trends Immunol 2001; 22:175-178.
33. Worm M, Lee HH, Kleine-Tebbe J, et al. Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy. J Allergy Clin Immunol 2011; 127:89-97.
34. Patel D, Couroux P, Hickey P, et al. Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo-controlled study. J Allergy Clin Immunol 2013; 131: 103-109.
35. Pellaton C, Perrin Y, Boudousquie C, et al. Novel birch pollen specific immunotherapy formulation based on contiguous overlapping peptides. Clin Transl Allergy 2013; 3:17.
36. Ellis AK, Frankish CW, Armstrong K, et al. A short course of synthetic peptide immuno-regulatory epitopes derived from grass allergens leads to a reduction in grass allergy symptoms. Allergy 2014; 69:s99: 32.
37. Hafner RP, Couroux P, Armstrong K, et al. Four doses of Der p derived synthetic peptide immuno-regulatory epitopes over 3 months results in a persistent treatment effect at 1 year on symptoms of house dust mite allergy. Allergy 2014; 69:s99: 31.
38. Shamji MH, Ceuppens J, Hellings P, et al. Immunogenicity evaluation of subcutaneous administration of peptide hydrolysate from Lolium perenne (gpASIT+TM) in combination with bacterial HSP70 (DnaK) in patients with seasonal allergic rhinitis. Allergy 2014; 69:s99: 31.
39. Jutel M, De Blay F, Jacobsen L, et al. AllerTTM: safety and efficacy of a birchpollen allergy vaccine based on contiguous overlapping peptides in a phase IIb study. Allergy 2014; 69:s99: 32.
40. Saarne T, Neimert-Andersson T, Gronlund H, et al. Treatment with a Fel d 1 hypoallergen reduces allergic responses in a mouse model for cat allergy. Allergy 2011; 66:255-263.
41. Meyer W, Narkus A, Salapatek AM, Hafner D. Double-blind, placebo-controlled, dose-ranging study of new recombinant hypoallergenic Bet v 1 in an environmental exposure chamber. Allergy 2013; 68:724-731.
42. Fili L, Cardilicchia E, Maggi E, Parronchi P. Perspectives in vaccine adjuvants for allergen-specific immunotherapy. Immunol Lett 2013; 161:207-210.
43. Hammad H, Chieppa M, Perros F, et al. House dust mite allergen induces asthma via toll-like receptor 4 triggering of airway structural cells. Nat Med 2009; 15:410-416.
44. Fili L, Vultaggio A, Cardilicchia E, et al. A novel allergen-adjuvant conjugate suitable for specific immunotherapy of respiratory allergy. J Allergy Clin Immunol 2013; 132:84-92.
45. Crameri R, Kundig TM, Akdis CA. Modular antigen-translocation as a novel vaccine strategy for allergen-specific immunotherapy. Curr Opin Allergy Clin Immunol 2009; 9:568-573.
46. Grundstrom J, Neimert-Andersson T, Kemi C, et al. Covalent coupling of vitamin D3 to the major cat allergen Fel d 1 improves the effects of allergen-specific immunotherapy in a mouse model for cat allergy. Int Arch Allergy Immunol 2012; 157:136-146.
47. Weiss R, Scheiblhofer S, Machado Y, Thalhamer J. New approaches to transcutaneous immunotherapy: targeting dendritic cells with novel allergen conjugates. Curr Opin Allergy Clin Immunol 2013; 13:669-676.
48. Neimert-Andersson T, Thunberg S, Swedin L, et al. Carbohydrate-based particles reduce allergic inflammation in a mouse model for cat allergy. Allergy 2008; 63:518-526.
49. Chen KW, Blatt K, Thomas WR, et al. Hypoallergenic Der p 1/Der p 2 combination vaccines for immunotherapy of house dust mite allergy. J Allergy Clin Immunol 2012; 130:435-443.
50. Chen KW, Focke-Tejkl M, Blatt K, et al. Carrier-bound nonallergenic Der p 2 peptides induce IgG antibodies blocking allergen-induced basophil activation in allergic patients. Allergy 2012; 67:609-621.
51. Klunker S, Saggar LR, Seyfert-Margolis V, et al. Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding. J Allergy Clin Immunol 2007; 120:688-695.
52. Wilson DR, Lima MT, Durham SR. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 2005; 60: 4-12.
53. Lin SY, Erekosima N, Kim JM, et al. Sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systematic review. JAMA 2013; 309:1278-1288.
54. Durham SR, Emminger W, Kapp A, et al. Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J Allergy Clin Immunol 2010; 125: 131-138.
55. Bufe A, Eberle P, Franke-Beckmann E, et al. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol 2009; 123:167-173.
56. Scadding GW, Shamji MH, Jacobson MR, et al. Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cells. Clin Exp Allergy 2010; 40:598-606.
57. Allam JP, Peng WM, Appel T, et al. Toll-like receptor 4 ligation enforces tolerogenic properties of oral mucosal Langerhans cells. J Allergy Clin Immunol 2008; 121:368-374.
58. Palomares O, Rückert B, Jartti T, et al. Induction and maintenance of allergen-specific FOXP3+ Treg cells in human tonsils as potential first-line organs of oral tolerance. J Allergy Clin Immunol 2012; 129:510-520.
59. Zhou Y, Kawasaki H, Hsu SC, et al. Oral tolerance to food-induced systemic anaphylaxis mediated by the C-type lectin SIGNR1. Nat Med 2010; 16:1128-1133.
60. Tourdot S, Airouche S, Berjont N, et al. Efficacy of sublingual vectorized recombinant Bet v 1a in a mouse model of birch pollen allergic asthma. Vaccine 2013; 31:2628-2637.